Artemis Medicare Q1 FY27: Robust Growth Continues with Record Profitability

The quarter's performance represents a continuation of the company's strong operational momentum, with net sales reaching a record ₹287.32 crores in Q1 FY27, up 2.90% sequentially and 12.69% year-on-year. What stands out is the marked improvement in profitability metrics across the board, with operating profit (PBDIT excluding other income) climbing to ₹56.44 crores and delivering a margin of 19.64%, the highest in at least eight quarters. This operational excellence has translated into superior bottom-line performance, with the PAT margin expanding to 10.94% from 8.32% in the corresponding quarter last year.

Following the results, Artemis Medicare's shares have demonstrated strong momentum, trading well above all key moving averages. The stock has generated an impressive 41.86% return over the past six months, significantly outperforming the Sensex which declined 6.12% during the same period, delivering an alpha of 47.98%. The current price of ₹304.15 represents a 49.94% gain from its 52-week low of ₹202.85, reflecting growing investor confidence in the company's growth trajectory.

Financial Performance: Margin Expansion Drives Profitability

Artemis Medicare's Q1 FY27 results showcase the company's ability to drive both top-line growth and margin expansion simultaneously. Net sales of ₹287.32 crores represent the highest quarterly revenue in the company's recent history, driven by improved capacity utilisation and a favourable patient mix. The sequential growth of 2.90% from Q4 FY26's ₹279.23 crores indicates sustained operational momentum, whilst the 12.69% year-on-year growth demonstrates the company's ability to capture market share in the competitive Delhi-NCR healthcare landscape.

The quality of earnings in Q1 FY27 is particularly noteworthy. Operating profit excluding other income surged to ₹56.44 crores, translating to a margin of 19.64%, up significantly from 16.24% in Q1 FY26. This 340 basis points year-on-year expansion reflects improved operational efficiency, better cost management, and enhanced pricing power. Employee costs, whilst rising to ₹42.84 crores from ₹38.40 crores last year, remained well-controlled as a percentage of revenue, indicating judicious hiring and productivity improvements.

On the profitability front, profit before tax reached ₹42.63 crores in Q1 FY27, up 43.17% year-on-year from ₹29.78 crores. The tax rate of 26.25% remained relatively stable, resulting in a consolidated net profit of ₹31.31 crores. The PAT margin of 10.94% represents a substantial improvement from 8.32% in the year-ago quarter, underscoring the company's ability to convert revenue growth into bottom-line expansion. This margin improvement is particularly impressive given the capital-intensive nature of the hospital business and the competitive pressure in the sector.

Operational Excellence: Efficiency Gains and Debt Management

Beyond the headline numbers, Artemis Medicare's operational performance in Q1 FY27 reveals a company hitting its stride across multiple dimensions. The operating profit to interest coverage ratio reached 8.74 times during the quarter, the highest level in recent periods, indicating robust debt servicing capability and financial stability. This improvement stems from both rising operating profits and declining interest costs, which fell to ₹6.46 crores in Q1 FY27 from ₹7.38 crores in Q1 FY26, reflecting the company's deleveraging efforts.

The company's balance sheet as of March 2026 shows shareholder funds of ₹934.71 crores, up from ₹837.68 crores a year earlier, driven by retained earnings and improved profitability. Long-term debt stood at ₹189.95 crores, resulting in a debt-to-equity ratio of 0.28 times, amongst the lowest in the peer group. The debt-to-EBITDA ratio of 1.39 times indicates strong ability to service debt from operating cash flows, providing financial flexibility for future expansion.

Return on capital employed (ROCE) for the trailing twelve months stood at 14.15%, whilst return on equity (ROE) reached 11.33%. Whilst these returns are respectable for a capital-intensive hospital business, they remain below the levels achieved by some premium peers. However, the improving trend is encouraging – the company achieved its highest half-yearly ROCE of 14.21% in the first half of FY26, suggesting that returns are moving in the right direction as operational leverage kicks in.

Cash flow generation remained healthy, with the company generating ₹131 crores from operations in FY2026, though this was partially offset by capital expenditure of ₹90 crores as the company continues to invest in upgrading facilities and equipment. The closing cash position as of March 2026 stood at ₹33 crores, down from ₹41 crores a year earlier, reflecting the company's ongoing investment cycle. Working capital management appears sound, with current assets of ₹366.85 crores comfortably covering current liabilities of ₹210.81 crores.

Industry Positioning: Capitalising on Healthcare Demand

Artemis Medicare operates in India's rapidly expanding private healthcare sector, which continues to benefit from rising incomes, increasing health awareness, growing insurance penetration, and demographic shifts. The company's flagship Artemis Hospital in Gurugram, operational since July 2007, is strategically positioned in one of India's most affluent and fastest-growing urban centres, serving both domestic patients and international medical tourists.

The hospital sector has demonstrated resilience and growth potential, with Artemis Medicare's 21.50% five-year sales compound annual growth rate (CAGR) outpacing many peers. More impressively, the company's operating profit has grown at a CAGR of 59.20% over the past five years, reflecting significant operating leverage as the hospital achieves scale and improves capacity utilisation. This growth trajectory has been supported by India's under-penetrated healthcare infrastructure, particularly in the premium segment where Artemis operates.

However, the sector also faces challenges including intense competition from established hospital chains, regulatory complexities, rising employee costs, and pressure on realisations from insurance companies. The capital-intensive nature of the business requires continuous investment in equipment upgrades and facility maintenance, which can pressure returns on capital. Additionally, the sector's dependence on skilled medical professionals creates retention challenges in a competitive labour market.

Peer Comparison: Valuation and Performance Metrics

When compared to listed hospital sector peers, Artemis Medicare presents an interesting valuation proposition. The company trades at a price-to-earnings (P/E) ratio of 45.16 times trailing twelve-month earnings, below the hospital sector average of approximately 66 times. This discount appears despite the company's strong recent growth momentum and improving profitability metrics.

Artemis Medicare's ROE of 10.12% lags the peer group average, with companies like Jeena Sikho (39.36%) and Kovai Medical (19.55%) delivering significantly higher returns on equity. This lower profitability is reflected in the company's relatively modest price-to-book ratio of 5.12 times, compared to peers trading at higher multiples. However, the company's minimal leverage (debt-to-equity of 0.06) provides a strong balance sheet foundation that many peers lack.

The valuation discount relative to peers appears justified by the lower returns on equity, though the gap may narrow as Artemis continues to improve operational efficiency and scale. The company's strong recent profit growth trajectory, improving margins, and conservative balance sheet suggest that current valuations may offer reasonable value for patient investors willing to hold through the company's growth phase.

Valuation Analysis: Attractive Entry Point for Growth Investors

At the current market price of ₹304.15, Artemis Medicare trades at a P/E ratio of 45.16 times, representing a 31.6% discount to the hospital sector average of approximately 66 times. This valuation gap appears despite the company's superior recent growth metrics – net profit has grown 47.13% year-on-year in Q1 FY27, significantly outpacing most peers. The price-to-book value of 5.12 times, whilst elevated in absolute terms, is below the peer average of approximately 7.8 times, suggesting the market is not yet fully pricing in the company's improving return profile.

The enterprise value to EBITDA multiple of 25.71 times reflects the market's recognition of the company's improving profitability and growth prospects. However, the PEG ratio of 3.96 suggests the stock may be pricing in significant future growth expectations. Historical valuation analysis shows the stock's valuation grade has fluctuated between "Attractive" and "Very Attractive" over recent months, currently settling at "Attractive" as of October 2025, indicating reasonable value at current levels.

The dividend yield of 0.15%, whilst modest, reflects the company's strategy of retaining earnings to fund expansion. The latest dividend of ₹0.45 per share represents a conservative payout ratio of 7.49%, leaving ample room for future increases as profitability improves. The stock's proprietary Mojo score of 78 out of 100 places it firmly in "BUY" territory, up from a "HOLD" rating in June 2026, reflecting the improving fundamental and technical picture.

Shareholding Pattern: Institutional Confidence Building

The shareholding pattern of Artemis Medicare reveals a stable promoter base combined with growing institutional interest. Promoter holding stood at 58.39% as of June 2026, unchanged from the previous quarter but down from 66.53% in September 2025. This reduction reflects a stake sale that brought in new institutional investors, broadening the shareholder base without compromising promoter commitment.

Foreign institutional investor (FII) holding increased marginally to 12.29% in June 2026 from 12.19% in March 2026, representing a vote of confidence from international investors. The presence of 21 FII investors indicates diversified foreign interest. However, mutual fund holding declined to 1.30% from 1.69%, suggesting some domestic institutional investors have reduced positions, possibly due to profit-booking after the strong rally.

Total institutional holding (FII, mutual funds, insurance, and other DII) stood at 20.84% as of June 2026, a healthy level that provides liquidity whilst avoiding excessive institutional concentration. The non-institutional shareholding of 20.76% has been gradually increasing, reflecting growing retail investor interest in the stock. Notably, 44.53% of promoter shares are pledged, which warrants monitoring though the stable promoter holding suggests no immediate concerns.

Stock Performance: Momentum Accelerates Across Timeframes

Artemis Medicare's stock has delivered exceptional returns across multiple timeframes, significantly outperforming both the benchmark Sensex and the broader hospital sector. Over the past year, the stock has generated returns of 22.20% compared to the Sensex's decline of 2.88%, delivering an alpha of 25.08 percentage points. This outperformance has been even more pronounced in recent months, with the stock surging 41.86% over six months whilst the Sensex fell 6.12%.

The longer-term performance is even more impressive. Over three years, the stock has surged 145.28% compared to the Sensex's 19.73% gain, whilst the five-year return of 666.89% dwarfs the benchmark's 44.73% return. These stellar returns reflect the company's transformation from a loss-making entity in earlier years to a consistently profitable hospital operator with improving margins and returns.

From a technical perspective, the stock is in a confirmed bullish trend, trading above all key moving averages – the 5-day (₹295.73), 20-day (₹278.84), 50-day (₹271.38), 100-day (₹255.86), and 200-day (₹255.22) moving averages. The MACD indicator shows bullish signals on both weekly and monthly charts, whilst Bollinger Bands also indicate bullish momentum. The stock's beta of 1.35 indicates higher volatility than the market, classified as a "high beta" stock suitable for investors with higher risk tolerance.

Investment Thesis: Growth Story with Improving Returns

The investment case for Artemis Medicare rests on several compelling pillars. First, the company operates in one of India's most attractive healthcare markets – the affluent Delhi-NCR region – with a well-established brand and multi-speciality capabilities. Second, the company is demonstrating significant operating leverage, with margins expanding rapidly as capacity utilisation improves and fixed costs are absorbed over a larger revenue base. Third, the balance sheet is conservatively managed with minimal leverage, providing financial flexibility for organic expansion or strategic investments.

The company's quality assessment has improved to "Good" from "Below Average" in prior years, reflecting sustained improvement in financial performance. The five-year sales CAGR of 21.50% and operating profit CAGR of 59.20% demonstrate robust growth momentum. Institutional holdings of 20.84% provide validation from sophisticated investors, whilst the improving trend in quarterly financials suggests momentum is building.

However, the investment thesis is not without risks. The company's ROE of 10.12% and ROCE of 11.97%, whilst improving, remain below best-in-class peers, indicating room for further efficiency gains. The PEG ratio of 3.96 suggests the market may be pricing in aggressive growth expectations, leaving limited room for disappointment. The 44.53% promoter pledge, though stable, requires monitoring. Additionally, the capital-intensive nature of the hospital business means sustained investment will be required to maintain competitive positioning.

Key Strengths and Risk Factors

Outlook: What to Watch in Coming Quarters

Looking ahead, the key monitorables for Artemis Medicare include the sustainability of margin expansion, the company's ability to maintain double-digit revenue growth, progress on return metrics (ROE and ROCE), and any announcements regarding capacity expansion or new facility additions. The management's capital allocation decisions will be crucial – balancing growth investments with shareholder returns through dividends or buybacks. Additionally, tracking institutional shareholding patterns and promoter pledge levels will provide insights into investor sentiment and financial health.